Pacira BioSciences Gene Therapy Shows Sustained Knee Osteoarthritis Improvement

Pacira BioSciences Inc. (NASDAQ:PCRX) is one of the most undervalued small-cap stocks to buy according to analysts. On June 11, Pacira BioSciences announced new long-term follow-up data from its Phase 1 clinical trial of PCRX-201 (enekinragene inzadenovec), which is an investigational gene therapy for osteoarthritis of the knee.

The results were presented at the 2025 European Alliance of Associations for Rheumatology/EULAR Congress in Barcelona, Spain, and showed that a single intra-articular injection of PCRX-201 was well tolerated and led to sustained improvements in pain, stiffness, and function for up to 156 weeks in patients with moderate-to-severe osteoarthritis of the knee.

Pacira BioSciences Gene Therapy Shows Sustained Knee Osteoarthritis Improvement

A scientist in a lab coat holding a vial of drug encapsulation and a molecular structure diagram.

PCRX-201 utilizes Pacira’s proprietary high-capacity adenovirus (HCAd) gene therapy vector platform. It works by locally injecting into the knee joint to boost cellular production of interleukin-1 receptor antagonist (IL-1Ra), thereby blocking interleukin-1 pathway activation to alleviate chronic inflammation, pain, and improve function.

Pacira BioSciences Inc. (NASDAQ:PCRX) develops, manufactures, markets, distribution, and sells non-opioid pain management and regenerative health solutions to healthcare practitioners in the US.

While we acknowledge the potential of PCRX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PCRX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.